Theriva Biologics, Inc. Email Format

Biotechnology ResearchMaryland, United States11-50 Employees

Theriva Biologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for cancer and other diseases with high unmet medical need. Through its subsidiary, the firm is advancing oncolytic and enzyme-based programs, including an intratumoral and systemic approach to tumor cell death and to enhancing the effectiveness of co-administered cancer therapies, as well as agents aimed at reducing microbiome disruption and treating gastrointestinal and systemic conditions. The lead oncology candidate is VCN-01, an oncolytic virus designed to target tumor cells and overcome barriers within the tumor microenvironment to stimulate an anti-tumor immune response. In addition, the portfolio includes SYN-004 (ribaxamase) to protect the gut microbiome from broad-spectrum antibiotics and SYN-020, an enzyme-based therapy produced under cGMP conditions for GI and systemic indications. 

Headquartered in Rockville, Maryland, Theriva Biologics operates in the biotechnology research sector and maintains a clinical-development focus with activities spanning IV, intravitreal, and antitumoral delivery approaches. The company collaborates with other organizations and participates in academic and industry conferences to share emerging data from its clinical programs, including recent presentations related to VCN-01 in pancreatic cancer and ophthalmic applications. Theriva Biologics positions itself as a diversified clinical-stage entity pursuing therapies that address cancers and related diseases where conventional treatments leave significant gaps.

Sign up for free to view info

Company overview Employee directory